Related Experiment Video
Updated: Aug 30, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
The development of differentiation agents for the treatment of prostate cancer
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
Given their novel mechanisms of action and relatively favorable toxicity profiles, differentiation agents have been the focus of much investigation in the field of oncology. Among the most well studied of these agents in prostate cancer have been the retinoids, vitamin D, peroxisome-proliferator-activated receptor gamma (PPARgamma) ligands, and, most recently, the histone deacetylase (HDAC) inhibitors. While the clinical activity of these agents has been limited, several obstacles to the development of these novel drugs have become apparent. A lack of validated measures of outcome and uncertainty regarding the appropriate disease states in which to test these agents have led to difficulty in trial design. Furthermore, a better understanding of the biologic targets and genes manipulated by these therapies is required such that more potent and selective drugs may be developed. By overcoming these obstacles, the full potential of this therapeutic class may be realized.
Insights
Differentiation agents show promise in oncology, particularly for prostate cancer. Overcoming challenges in trial design and target understanding is key to realizing their full therapeutic potential.
Area of Science:
- Oncology
- Pharmacology
Background:
- Differentiation agents are investigated for novel mechanisms and favorable toxicity in cancer.
- Retinoids, vitamin D, PPARgamma ligands, and HDAC inhibitors are studied for prostate cancer.
- Limited clinical activity and development obstacles hinder these agents.
Purpose of the Study:
- To review the challenges and potential of differentiation agents in oncology, specifically prostate cancer.
- To highlight the need for improved trial design and target understanding for these therapies.
Main Methods:
- Literature review of differentiation agents in prostate cancer.
- Analysis of obstacles in clinical development and trial design.
- Discussion of biologic targets and gene manipulation.
Main Results:
- Limited clinical activity observed for retinoids, vitamin D, PPARgamma ligands, and HDAC inhibitors.
- Key obstacles include lack of validated outcome measures and uncertainty in disease state selection for trials.
- A deeper understanding of therapeutic targets and gene modulation is required.
Conclusions:
- Differentiation agents hold therapeutic promise but face significant development hurdles.
- Addressing challenges in trial design and target identification is crucial for future drug development.
- Realizing the full potential of this drug class requires overcoming current limitations.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...